康宁杰瑞制药-B(09966)：KN026关键性II/III期临床试验期中分析达到PFS主要终点

智通财经2025-04-30

智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，本公司与石药集团有限公司(01093)附属公司上海津曼特生物科技有限公司合作开发的KN026(KN026- 001)联合化疗二线及以上治疗HER2阳性GC(包括GEJ)的II/III期临床试验已完成首个期中分析及期中分析结果达到PFS主要终点。KN026-001的第2部分是一项随机、双盲、安慰剂对照的III期研究，旨在评估 KN026联合...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531035965?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-30 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531035965","market":"hk","top_or_hot":-1,"title":"康宁杰瑞制药-B(09966)：KN026关键性II/III期临床试验期中分析达到PFS主要终点","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，本公司与石药集团有限公司(01093)附属公司上海津曼特生物科技有限公司合作开发的KN026(KN026- 001)联合化疗二线及以上治疗HER2阳性GC(包括GEJ)的II/III期临床试验已完成首个期中分析及期中分析结果达到PFS主要终点。KN026-001的第2部分是一项随机、双盲、安慰剂对照的III期研究，旨在评估 KN026联合...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1288556.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康宁杰瑞制药-B(09966)：KN026关键性II/III期临床试验期中分析达到PFS主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康宁杰瑞制药-B(09966)：KN026关键性II/III期临床试验期中分析达到PFS主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-30 19:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1288556.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，本公司与石药集团有限公司(01093)附属公司上海津曼特生物科技有限公司合作开发的KN026(KN026- 001)联合化疗二线及以上治疗HER2阳性GC(包括GEJ)的II/III期临床试验已完成首个期中分析及期中分析结果达到PFS主要终点。KN026-001的第2部分是一项随机、双盲、安慰剂对照的III期研究，旨在评估 KN026联合...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1288556.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1288556.html","article_id":"2531035965","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531035965","pubTimestamp":1746012652,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，本公司与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的KN026联合化疗二线及以上治疗HER2阳性GC的II/III期临床试验已完成首个期中分析及期中分析结果达到PFS主要终点。KN026-001研究第2部分的首个PFS期中分析结果已由独立数据监察委员会 审查，结果显示达到预先设定的PFS的主要终点，具有统计学显著性和临床意义。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"III":"信息服务","BK4134":"信息科技咨询与其它服务","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","PFS":"Provident Financial Services Inc","BK1576":"医药外包概念","BK4211":"区域性银行","BK1161":"生物科技","09966":"康宁杰瑞制药-B","03347":"泰格医药","BK1574":"生物医药B类股","BK4195":"互助储蓄与抵押信贷金融服务"},"translate_title":"Alphamab-B (09966): Interim analysis of KN026 pivotal phase II/III clinical trial reached the primary endpoint of PFS","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFS":1,"09966":1,"III":1,"03347":1},"content_text":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，本公司与石药集团有限公司(01093)附属公司上海津曼特生物科技有限公司合作开发的KN026(KN026- 001)联合化疗二线及以上治疗HER2阳性GC(包括GEJ)的II/III期临床试验已完成首个期中分析及期中分析结果达到PFS主要终点。KN026-001的第2部分是一项随机、双盲、安慰剂对照的III期研究，旨在评估 KN026联合化疗用于一线标准治疗失败的HER2阳性晚期不可切除或转移性GC(包括GEJ)患者的疗效。该研究的主要终点为经独立评审委员会(IRC)评估的PFS 和总生存期(OS)。KN026-001研究第2部分的首个PFS期中分析结果已由独立数据监察委员会 (IDMC)审查，结果显示达到预先设定的PFS的主要终点，具有统计学显著性和临床意义。PFS期中分析结果显示，与现有标准治疗相比，KN026联合化疗显著改善了患者的PFS，降低了疾病进展╱死亡的风险，并具有OS获益趋势。该研究的详细数据将在近期国际学术会议上公布。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531035965","isCrawlerRequest":true}